Christian la Fougère

Nov 17, 2024 | nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more

AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.

Nov 17, 2024 | nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more

AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.

Aug 10, 2024 | nature.com | Pauline Latzer |Florian Battke |Till-Karsten Hauser |Christian la Fougère |Uwe M. Martens |Deborah Blumenthal | +8 more

AbstractCurrent treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt.

Jul 10, 2023 | nature.com | Nicole McKay |Brian Gordon |Shaney Flores |Nelly Joseph-Mathurin |Clifford R. Jack |Peter Millar | +19 more

All data described in the current resource manuscript are freely available upon completion of a DIAN-OBS Data Request Form. This request procedure allows DIAN to implement a transparent and inclusive data-sharing practice while maximizing confidentiality and security of our participants’ protected personal information. Every submission is reviewed by the DIAN principal investigator as well as relevant DIAN core leaders (that is, the Imaging Core leader).